ELISA News and Research

RSS

AquaStar granted U.S. Patent for Portable Capillary Sensor technology used in Capwave ELISA platform

AquaStar Holdings, Inc. is pleased to announce that the United States Patent and Trademark Office has issued patent number 7,708,944 for the Ultra-Sensitive, Portable Capillary Sensor technology utilized by the Capwave Enzyme-Linked Immuno-Sorbent Assay (ELISA) platform.

28 Apr 2011

Mount Sinai's new Dubin Breast Center to provide patients with seamless care

The new Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai opened today, bringing a range of multidisciplinary services under one roof and marking a great leap forward in care of breast cancer patients throughout the region.

19 Apr 2011

New dengue test receives FDA marketing clearance

The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

11 Apr 2011

Axxora.com to distribute TGR's new ELISAONE technology assay reagents in the US and South America

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Axxora.com of San Diego, CA, US, a leading online global market place resource for innovative and high quality Life Science research reagents.

4 Apr 2011

World Stem Cell Report to be published in Regenerative Medicine

The Genetics Policy Institute (GPI) and Future Medicine have announced that its 2011/12 World Stem Cell Report will be published as a special supplement to the award- winning, peer-reviewed journal Regenerative Medicine. It was also announced that Regenerative Medicine becomes the platinum media sponsor of the GPI’s 2011 World Stem Cell Summit that will take place in Pasadena, California, October 3-5.

31 Mar 2011

Diabetes management accepted for coverage by Chemical Abstracts

Future Medicine Ltd announces today that its new journal Diabetes Management (ISSN 1758-1907) which launched in January 2011 has been selected for coverage by Chemical Abstracts.

24 Mar 2011

Enzo Life Sciences introduces ELISA system to detect SMN protein

Enzo Biochem, Inc. and the Spinal Muscular Atrophy Foundation today announced that Enzo's wholly owned subsidiary, Enzo Life Sciences Inc., has launched a unique immunoassay system which can be used for the identification and detection of Survival Motor Neuron protein.

16 Mar 2011

Alzheimer's vaccine - First evidence for efficacy

AFFiRiS' Alzheimer's vaccine candidate AD02 showed indicative evidence for potential efficacy in a phase I clinical trial. This was demonstrated by the analysis of the data from secondary clinical study endpoints.

12 Mar 2011

Future Medicine launches Neuropsychiatry

Future Medicine Ltd has today announced the launch of Neuropsychiatry – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world. Neuropsychiatry is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

10 Mar 2011

Neurodegenerative Disease Management – meeting the challenge of neurodegenerative diseases

Future Medicine Ltd has today announced the launch of Neurodegenerative Disease Management – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world.

3 Mar 2011

Bioanalysis accepted for coverage by EMBASE & Scopus

EMBASE is a premier online resource for biomedical literature, with over 24 million indexed records and more than 7,500 current, mostly peer-reviewed journals, EMBASE quickly and accurately delivers biomedical answers. Scopus is the largest abstract and citation database of research literature and quality web sources covering nearly 18,000 titles from more than 5,000 publishers.

1 Mar 2011

Seaweed microsponges may help diagnose many diseases quickly, at far lower cost

Microsponges derived from seaweed may help diagnose heart disease, cancers, HIV and other diseases quickly and at far lower cost than current clinical methods. The microsponges are an essential component of Rice University's Programmable Bio-Nano-Chip (PBNC) and the focus of a new paper in the journal Small.

9 Feb 2011

Bruker launches new fully automated and fast toxin identification system

Bruker today announces the North American launch of its compact, fully automated and fast toxin identification system, called pTD™ (portable Toxin Detector), at the American Society for Microbiology (ASM) Bio-Defense and Emerging Diseases Research Meeting in Washington, DC. The novel, benchtop, push-button pTD system is intended for smaller, field and mobile laboratories for use by non-expert operators in homeland security applications.

7 Feb 2011

Diabetes Management – a new journal addressing the management issues of a complex disease

Future Medicine Ltd has today announced the launch of Diabetes Management – a new bimonthly title presenting findings, analyses and commentaries on the battle with Type 1 and Type 2 diabetes. Diabetes Management is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

6 Feb 2011

Silicon dioxide coated rust nanoparticles to fight cervical cancer

The next big thing in medical diagnostics could be minutes particles of rust, iron oxide, coated with the material from which sand is formed, silicon dioxide. These magnetic nanoparticles, a mere 29 to 230 nanometers across, can be used to trap antibodies to the virus that causes cervical cancer and to the bacteria that causes potentially lethal diarrhea.

1 Feb 2011

New research identifies nutrition inadequacy among Americans

At a time when the country is facing an obesity epidemic, the problem of nutrition inadequacy is often overlooked. Yet, many Americans are overweight and undernourished, concludes a new study called "What America's Missing."

12 Jan 2011

Expansion of HIV screening worthwhile

According to researchers, screening for the AIDS virus to include every American at least once and the highest-risk people once a year could prevent more than 80,000 infections over the next 20 years. The team from Yale University in Connecticut and Stanford University in California reported that if treatment for infected people were integrated into such a program, it would prevent an estimated 212,000 new infections.

21 Dec 2010

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

13 Dec 2010

First genetic test on developing risk of Alzheimer's disease and heart attacks

Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using a simple blood test".

10 Dec 2010

MP receives FDA IND approval for clinical trial with HTLV-I/II ELISA 4.0 and HTLV Blot.2.4

MP Biomedicals LLC announced today that it has received approval of its investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to start pivotal clinical trials in the USA with the MP Diagnostics™ HTLV-I/II ELISA 4.0 and HTLV Blot.2.4. Studies will be conducted within the American Red Cross, the California Department of Public Health, and LABS, Inc. The company is working closely with the principal investigator of the American Red Cross sites, Dr. Susan Stramer, Executive Scientific Officer.

From MP Biomedicals, LLC 7 Dec 2010